Authors
Lidya Agriningsih Haruna, La Ode Muh Julian Purnama, Adryan Fristiohady, Sewan Theeramunkong, Promsin Masrinoul, Jukrapun Komaikul, Kunjimas Ketsuwan, Rathapon Asasutjarit
Published in
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. Pages 115296. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
Herpes simplex virus (HSV)-1-induced retinitis is a serious ocular infection. Although intravitreal (IVT) injection of ganciclovir (GCV) is currently accepted as one of its treatment methods, frequent IVT injection causes some complications. To overcome this limitation, folate-chitosan nanoparticles containing GCV (GCV-FCS-NPs) were prepared. The objectives of this study were 1) to prepare and characterize GCV-FCS-NPs, 2) to evaluate their in vitro bioactivities, and 3) to assess pharmacokinetics of GCV following IVT injection of GCV-FCS-NPs in the rats' eyes. Folate-chitosan was synthesized via a carbodiimide reaction. Then, GCV-FCS-NPs were prepared by an ionic gelation technique. The obtained GCV-FCS-NPs had a particle size of 195 nm with moderate size distribution and positive charges. Their entrapment efficiency was around 21 %. Cellular uptake studies showed that GCV-FCS-NPs could significantly enhance GCV internalization in the ARPE-19 cells. Their IC50 against HSV-1 was 11.75 ± 1.82 µg/mL. Pharmacokinetic studies demonstrated that GCV-FCS-NPs provided higher AUC and longer half-life of GCV in the vitreous humor when compared to that of GCV from GCV solution. Furthermore, IVT injection of GCV-FCS-NPs did not cause harmful side effects in the rats' eyes. These findings indicate the potential of GCV-FCS-NPs for ocular delivery of GCV via IVT injection.
PMID:
43033874
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0